Brand and Other Names:Zovirax topical, Sitavig
- Classes: Antivirals, Topical
Dosing & Uses
Dosing Strengths & Forms
mucoadhesive buccal tablet
- 50mg (Sitavig)
- Limited, non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients
- Apply topically to lips and around mouth 5 times per day for 4 days; initiate as soon as possible after first signs and symptoms
Mucoadhesive buccal tablet
- Recurrent herpes labialis (cold sores) in immunocompetent adults
- Apply one 50 mg buccal tablet as a single dose to the upper gum (canine fossa) region
- Should be applied within 1 hr after the onset of prodromal symptoms and before the appearance of any signs of Herpes labialis
Initial genital herpes
Apply sufficient quantity to adequately cover all lesions q3hr, 6 times/day for 7 days
Herpetic Keratitis (Orphan)
Acute herpetic keratitis caused by Herpes simplex virus types 1 and 2
Orphan indication sponsors
- GlaxoSmithKline, One Franklin Plaza, Philadelphia, PA 19101
- Fera Pharmaceuticals, 134 Birch Hill Road, Locust Valley, NY 11560
- The dose size per application will vary depending on the total lesion area but should approximate a one-half-inch ribbon of ointment per 4 square inches of surface area
- A finger cot or rubber glove should be used when applying, to prevent autoinoculation of other body sites and transmission of infection to other persons
Mucoadhesive buccal tablet
- Do not crush, chew, suck, or swallow tablets
Dosing Strengths & Forms
Recurrent herpes labialis (cold sores) in adults and adolescents
<12 years: Safety and efficacy not established
≥12 years: As adults, apply cream/ointment topically to lips and around mouth 5 times per day for 4 days; initiate as soon as possible after first signs and symptoms
Dry lips (<1%)
Frequency Not Defined
Not recommended for recurrent infections
Use caution in immunocompromised patients
Avoid physical contact when lesions are present
For external use only; not for use on the eye or inside mouth
Pregnancy & Lactation
Pregnancy category: B
Lactation: Excretion in milk unknown; systemic exposure is minimal after topical application
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Exerts its antiviral effect on herpes simplex viruses and varicella zoster virus by interfering with DNA synthesis and inhibiting viral replication
Helps shed herpes virus quicker and reduces pain and duration; used for management of initial episodes of herpes genitalis and in mucocutaneous herpes simplex viral infections in immunocompromised patients
In cells infected with herpes viruses, principally by intracellular phosphorylation of drug by virus-coded thymidine kinase and several cellular enzymes
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs